Cholesterol and Heart Risk: Reading Your Lipid Panel

A lipid panel is one of the few tests where the printout tells you almost nothing on its own. The same LDL number can be entirely unremarkable in one person and the most important thing on the page in another. What follows is how to read the whole panel, what the newer tests add, and how the numbers become an actual risk estimate.

What cholesterol is doing in the body#

Cholesterol is not a poison that got into your blood. It is a structural molecule in every cell membrane, the raw material for cortisol, testosterone, estrogen and vitamin D, and a component of bile acids. Your liver makes most of it. Dietary cholesterol, the egg question, has a much smaller effect on blood levels than was believed for decades.

The problem is transport. Cholesterol does not dissolve in blood, so it travels inside lipoproteins: spheres with a fatty core and a protein shell. Think of them as delivery vans on a road network.

Each artery-damaging van carries exactly one copy of a protein called apolipoprotein B (ApoB). LDL, VLDL, IDL and Lp(a) all carry it. HDL does not. When too many ApoB vans are in circulation, some slip into the artery wall, get trapped by the connective tissue there, become oxidised, and provoke an immune response. That inflammatory response is atherosclerosis. Plaque is not cholesterol sludge sticking to a pipe; it is a chronic inflammatory lesion inside the wall of the pipe.

This is why the number of ApoB particles predicts risk better than the amount of cholesterol they are carrying. Two people with identical LDL cholesterol can have very different particle counts. One with fewer, larger vans, one with many small ones. The second person is at higher risk despite an identical LDL result.

Reading the panel, line by line#

A few notes that make the table more useful.

LDL is usually calculated, not measured. Most labs derive it using an equation, which becomes unreliable when triglycerides are above about 400 mg/dL (4.5 mmol/L) or when LDL is very low. Non-HDL and ApoB do not have this weakness.

LDL at or above 190 mg/dL (4.9 mmol/L) in an adult should always prompt the question of familial hypercholesterolaemia. An inherited condition affecting roughly 1 in 250 people worldwide, which is far more common than most doctors assume and is heavily underdiagnosed. It matters because relatives can be tested.

Triglycerides above 500 mg/dL (5.6 mmol/L) shift the concern from arteries to the pancreas, and above 880 mg/dL (10 mmol/L) the risk of acute pancreatitis becomes significant. High triglycerides with low HDL is also the classic fingerprint of insulin resistance.

HDL is not a lever. Low HDL is a reliable marker of higher risk. But drugs that raised HDL substantially failed, repeatedly, to reduce heart attacks, and genetic studies show no causal protective effect. Treat a low HDL as information about metabolic health, not a target.

The two tests most people have never been offered#

ApoB#

ApoB directly counts artery-damaging particles. It is most valuable when LDL and particle count disagree, which happens in insulin resistance, type 2 diabetes, high triglycerides, and in people with a normal-looking LDL who nonetheless have events. It is a cheap, widely available, standardised test. Broadly, below 90 mg/dL is considered acceptable for average risk, with lower figures used for people at high or very high risk.

Lp(a)#

Lipoprotein(a) is an LDL particle with an additional protein, apolipoprotein(a), attached. It is both atherogenic and prothrombotic, and it also drives calcific aortic valve disease.

Three things make it unusual. First, your level is set by genetics and stays roughly constant for life: diet, exercise and statins barely move it. Second, around one in five people has a raised level, so it is common. Third, it explains a real fraction of heart attacks in people whose conventional panel looks fine, and it is markedly more common in people of South Asian and African ancestry.

Because it does not change, testing once in adult life is enough. A raised result does not mean treatment for the Lp(a) itself; it means your other risk factors should be managed more assertively, and your first-degree relatives should be tested. Medications targeting Lp(a) directly are in late-stage trials but are not yet established practice.

How risk calculators turn numbers into decisions#

No credible guideline treats cholesterol in isolation. A 62-year-old smoker with diabetes and an LDL of 130 mg/dL is in a completely different situation from a 34-year-old non-smoker with the same LDL.

Risk calculators combine age, sex, blood pressure, smoking, diabetes, cholesterol and other variables into an estimated probability of a cardiovascular event over a defined period.

Two caveats worth knowing. All of these tools were built on specific populations and travel imperfectly, generally under-estimating risk in South Asian populations unless the tool corrects for it, as QRISK3 does. And they estimate a population average for people like you; they cannot tell you what will happen to you.

When a result lands in a gray zone, clinicians look at risk enhancers: family history of premature heart disease, raised Lp(a), persistently high triglycerides, chronic inflammatory disease, chronic kidney disease, pregnancy complications such as pre-eclampsia or gestational diabetes, and South Asian ancestry. A coronary artery calcium (CAC) score from a low-dose CT can also settle the question. A score of zero in an intermediate-risk person is a powerful piece of reassurance, while a high score reclassifies upward.

What statins do, at a class level#

Statins block HMG-CoA reductase, the rate-limiting enzyme the liver uses to make cholesterol. The liver responds to having less internal cholesterol by putting more LDL receptors on its surface, and those receptors pull ApoB particles out of the bloodstream. The main effect is therefore increased clearance rather than reduced production.

The evidence base is unusually large. Pooled analyses of trials covering many tens of thousands of participants show that each 1 mmol/L (about 39 mg/dL) reduction in LDL is associated with roughly a 20 to 25 per cent proportional reduction in major vascular events per year of treatment, and that the benefit continues to accrue the longer treatment is taken. The proportional benefit is similar across groups; the absolute benefit depends on your starting risk, which is exactly why risk calculators exist.

On harms, the honest summary is:

• Muscle symptoms. Serious muscle injury is rare. Of the order of 1 to 3 cases per 100,000 person-years. Aches are reported far more often, but blinded n-of-1 studies, where participants took statin and placebo in randomly ordered months without knowing which, found that the great majority of symptom burden occurred equally in placebo months. This does not mean the symptoms are imagined; it means the cause is often not the drug.
• New-onset diabetes. A small real excess, on the order of one additional case per 200 to 250 people treated per year, concentrated in people already close to the threshold.
• Liver enzymes. Mild rises are common and rarely significant. Serious liver injury is very rare.

Other lipid-lowering classes exist and work by different mechanisms: ezetimibe reduces intestinal cholesterol absorption, PCSK9 inhibitors increase LDL receptor recycling, bempedoic acid acts upstream of the statin target, and fibrates and purified omega-3 preparations are used mainly for high triglycerides.

What actually changes the numbers without medication#

• Replacing saturated fat with unsaturated fat is the highest-yield dietary change for LDL, typically 5 to 10 per cent.
• Soluble fiber from oats, barley, pulses, apples and psyllium: around 5 to 10 per cent with consistent intake.
• Plant sterols and stanols, found in fortified spreads: roughly 5 to 10 per cent.
• Reducing refined carbohydrate and alcohol is the main lever for triglycerides, which can fall 20 to 50 per cent, sometimes dramatically.
• Aerobic exercise raises HDL modestly and lowers triglycerides, with little direct effect on LDL.
• Stopping smoking does not change LDL much but changes cardiovascular risk more than almost anything else on this list.

Combining several of these can lower LDL by 15 to 25 per cent. Real, but rarely enough for someone with very high levels or established disease.

Oversold: red yeast rice, which contains a naturally occurring statin at unpredictable and unregulated concentrations, so it carries statin-like effects and risks without statin-like quality control. Garlic tablets, policosanol and most "cholesterol support" supplements do not survive good trials. Fish oil capsules at supermarket doses lower triglycerides slightly and do not reduce events.

What I see in clinic#

Two patterns come up again and again.

The first is the person who is fixated on total cholesterol. They have a total of 210 mg/dL, an excellent HDL, low triglycerides and no other risk factors, and they are frightened. Their actual risk is low. Total cholesterol is the least useful number on the page, and it is the one printed at the top.

The second is the opposite, and it worries me more: a slim, active, non-smoking man in his forties whose panel looks entirely normal and whose father died at 52. Nobody has checked his Lp(a) or asked properly about the family history, because he does not look like the picture in the textbook. Familial hypercholesterolaemia and raised Lp(a) both hide behind looking well.

The question I get asked most is about eggs. The short answer: for most people, dietary cholesterol has a modest effect on blood cholesterol, and the saturated fat cooked alongside the egg usually matters more than the egg.

At work#

Occupational medicals are where a large number of lipid abnormalities are first found, in people who feel perfectly well and would not otherwise have been tested. Take the result seriously enough to keep a copy and track it over years. The trend is more informative than any single panel.

Two occupational patterns are real. Shift work is associated with an unfavourable lipid profile, higher triglycerides, lower HDL, through circadian misalignment and the timing of eating, independent of what is eaten. And sedentary roles, whether at a control desk or in a vehicle cab, are associated with higher triglycerides in a way that structured exercise only partly offsets; breaking up sitting through the shift appears to matter separately from formal exercise.

There is also a fairness point. Fitness-for-work assessments sometimes flag cholesterol without providing any route to follow-up. A number without a next step is not screening; it is just anxiety with a letterhead.

When to get help now#

Chest pressure or tightness, particularly on exertion, or spreading to the jaw, neck, back or arm, or with breathlessness, sweating or nausea: is an emergency and needs immediate assessment. So is sudden one-sided weakness, facial droop or difficulty speaking.

Seek prompt review for triglycerides above 500 mg/dL (5.6 mmol/L), for LDL of 190 mg/dL (4.9 mmol/L) or above, for tendon thickening at the ankles or yellow deposits around the eyelids, and for new calf pain that comes on with walking and settles with rest.

Book a routine appointment to discuss testing if you have a parent or sibling who had a heart attack or stroke early, if you have diabetes, kidney disease or an inflammatory condition, or if you have simply never had a lipid panel and are over 40, or over 25 with a strong family history.

The bottom line#

Cholesterol is not the villain; the number of ApoB-carrying particles slipping into artery walls is. Read non-HDL rather than total cholesterol, ask about ApoB if your triglycerides are high or your risk feels underestimated, and consider measuring Lp(a) once, because it is common, inherited and almost never checked. A lipid result only becomes meaningful when it is put through a risk calculator alongside your age, blood pressure, smoking status and ethnicity. And decisions about medication belong to you and your own doctor, informed by that whole picture rather than by one line on a printout.